Literature DB >> 9666480

A prion protein fragment primes type 1 astrocytes to proliferation signals from microglia.

D R Brown1, B Schmidt, H A Kretzschmar.   

Abstract

Giliosis is a hallmark of prion disease. A neurotoxic prion peptide (PrP106-126) induces astrocyte proliferation in the presence of microglia. This peptide also directly enhances microglial proliferation in culture. We have investigated this further to understand the method by which factors released by microglia and PrP106-126 work together to enhance astrocyte proliferation. PrP106-126 in the presence of microglia specifically enhanced type 1 astrocyte proliferation but not Type 2. Astrocytes that do not express the prion protein were more sensitive to oxidative stress and the toxicity of cytosine arabinoside. In the presence of cytosine arabinoside, PrP106-126 was toxic to pure astrocyte cultures. Using conditioned medium from microglia we have shown that PrPc-expressing astrocytes proliferate in response to factors released by microglia stimulated by granulocyte/macrophage colony-stimulating factor. This response is enhanced in the presence of PrP106-126. PrPc-deficient astrocytes do not show this response. These results suggest that astrocytes are primed by PrP106-126 to respond more to factors released by proliferating microglia. Astrocytes may proliferate in this system to escape entering the cell suicide pathway.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9666480     DOI: 10.1006/nbdi.1998.0169

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  8 in total

Review 1.  Copper-dependent functions for the prion protein.

Authors:  David R Brown; Judyth Sassoon
Journal:  Mol Biotechnol       Date:  2002-10       Impact factor: 2.695

2.  Different Molecular Mechanisms Mediate Direct or Glia-Dependent Prion Protein Fragment 90-231 Neurotoxic Effects in Cerebellar Granule Neurons.

Authors:  Stefano Thellung; Elena Gatta; Francesca Pellistri; Valentina Villa; Alessandro Corsaro; Mario Nizzari; Mauro Robello; Tullio Florio
Journal:  Neurotox Res       Date:  2017-05-25       Impact factor: 3.911

3.  PrPSc-like prion protein peptide inhibits the function of cellular prion protein.

Authors:  D R Brown
Journal:  Biochem J       Date:  2000-12-01       Impact factor: 3.857

Review 4.  Protease resistant protein cellular isoform (PrP(c)) as a biomarker: clues into the pathogenesis of HAND.

Authors:  Bezawit Megra; Eliseo Eugenin; Toni Roberts; Susan Morgello; Joan W Berman
Journal:  J Neuroimmune Pharmacol       Date:  2013-04-25       Impact factor: 4.147

Review 5.  Recent advances in prion chemotherapeutics.

Authors:  Valerie L Sim; Byron Caughey
Journal:  Infect Disord Drug Targets       Date:  2009-02

6.  Neurotoxic and gliotrophic activity of a synthetic peptide homologous to Gerstmann-Sträussler-Scheinker disease amyloid protein.

Authors:  Luana Fioriti; Nadia Angeretti; Laura Colombo; Ada De Luigi; Alessio Colombo; Claudia Manzoni; Michela Morbin; Fabrizio Tagliavini; Mario Salmona; Roberto Chiesa; Gianluigi Forloni
Journal:  J Neurosci       Date:  2007-02-14       Impact factor: 6.167

Review 7.  p62-Keap1-NRF2-ARE Pathway: A Contentious Player for Selective Targeting of Autophagy, Oxidative Stress and Mitochondrial Dysfunction in Prion Diseases.

Authors:  Syed Zahid Ali Shah; Deming Zhao; Tariq Hussain; Naveed Sabir; Mazhar Hussain Mangi; Lifeng Yang
Journal:  Front Mol Neurosci       Date:  2018-10-04       Impact factor: 5.639

Review 8.  Microglia in Prion Diseases: Angels or Demons?

Authors:  Caterina Peggion; Roberto Stella; Paolo Lorenzon; Enzo Spisni; Alessandro Bertoli; Maria Lina Massimino
Journal:  Int J Mol Sci       Date:  2020-10-20       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.